FCEL FuelCell Energy reports narrower Q1 2026 loss shares jump 24 percent on 41 percent year over year revenue growth Bank of America Corporation BAC Outperforms Q1 2026 Earnings Estimates Amid Broad Banking Sector Upside GWAV Greenwave posts 66 yearoveryear Q3 2023 revenue decline shares dip 249 in todays session KraneShares CSI China Internet ETF KWEB Poised to Capture Upside as China Ends 3Year Factory Deflation Streak iQSTEL IQST Stock Rights Issue 621 20260420 RDGT Ridgetech reports Q3 2011 earnings miss and declining revenue shares fall 265 on weak quarterly performance ONB Old drops 263 after Q1 2026 EPS lands slightly below Wall Street consensus estimates American Tower Corporation AMT PreQ1 2026 Earnings Analysis Is It a Strategic Buy Ahead of Results Apple Leadership Transition and Strategic Outlook Analysis Where is Conoco COP stock heading next Smart Money Active 20260420 Avista AVA Stock Volume Spike Alert Market Focus 20260420 Lowes Companies Inc LOW Strategic Investment Playbook Positions Firm for Outperformance Amid Cyclical Housing Headwinds Ecolab Inc ECL Q1 2026 Earnings Preview Resilient Segment Growth Drives Bullish Consensus Projections Is Wheeler WHLRL stock struggling to move higher Wheeler posts 365 EPS with no analyst estimates TRUP Trupanion stock gains 23 percent even as its fourth quarter 2025 earnings per share miss analyst expectations OYSEU Oyster management details strategic acquisition search priorities as it evaluates highpotential private market targets BACC Blue Acq CEO signals sharp focus on highgrowth sector acquisitions in latest quarterly earnings call US Federal Housing Legislation SingleFamily Rental Market Regulatory Impact Analysis Is Brixmor BRX stock appealing for longterm investors Q4 2025 Earnings Beat Estimates US IEEPA Tariff Refund Program Launch Operational Update and Market Implications Cencora COR Stock Working Order Smart Money Exits 20260420 Verizon Communications Inc VZ Former Finance Executive Appointed to Key CSuite Roles at Abacus Global Management HALO Halozyme Therapeutics edges up 04 percent after Q4 2025 results with 375 percent revenue growth offsetting steep EPS miss